Vir Biotechnology Wins $50M BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology, Inc. (NASDAQ:VIR) has been awarded approximately $50 million in new funding by the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of novel monoclonal antibody candidates and delivery solutions for COVID-19 and pandemic preparedness and response.
October 03, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The $50 million funding from BARDA will help Vir Biotechnology advance its development of antibody solutions, potentially boosting its stock in the short term.
The funding will support Vir Biotechnology's development of novel monoclonal antibody candidates and delivery solutions for COVID-19 and pandemic preparedness. This could lead to potential revenue growth and increased investor confidence, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100